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EGFR Pathway Activity in Cutaneous Squamous
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Stanislaw A. Buechner2, Paul Erne3 and The´re`se J. Resink1
Genetic and epigenetic studies in different cancers, including cutaneous carcinomas, have implicated T-cadherin
(T-cad) as a tumor suppressor. Immunohistochemical and in vitro studies have suggested that T-cad loss
promotes incipient invasiveness in cutaneous squamous cell carcinoma (SCC). Molecular mechanisms are
unknown. This study found that the main consequence of T-cad silencing in SCC is facilitation of ligand-
dependent EGFR activation, whereas T-cad overexpression impedes EGFR activation. Gain- and loss-of-function
studies in A431 SCC cells demonstrate T-cad-controlled responsiveness to EGF with respect to pharmacological
inhibition of EGFR and to diverse signaling and functional events of the EGFR activation cascade (EGFR
phosphorylation, internalization, nuclear translocation, cell retraction/de-adhesion, motility, invasion, integrin
b1, and Rho small GTPases such as RhoA, Rac1, and Cdc42 activation). Further, T-cad modulates the EGFR pathway
activity by influencing membrane compartmentalization of EGFR; T-cad upregulation promotes retention of EGFR
in lipid rafts, whereas T-cad silencing releases EGFR from this compartment, rendering EGFR more accessible to
ligand stimulation. This study reveals a mechanism for fine-tuning of EGFR activity in SCC, whereby T-cad
represents an auxiliary ‘‘negative’’ regulator of the EGFR pathway, which impacts invasion-associated behavioral
responses of SCC to EGF. This action of T-cad in SCC may serve as a paradigm explaining other malignancies
displaying concomitant T-cad loss and enhanced EGFR activity.
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INTRODUCTION
Cutaneous squamous cell carcinoma (SCC), the second most
common form of nonmelanoma skin cancer, exhibits variable
degrees of atypia, invasiveness, and risk of metastasis (Alam
and Ratner, 2001). Cellular events participating in transfor-
mation from noninvasive to invasive and potentially meta-
static SCC are not well understood. Strict orchestration of
cell–cell and cell–matrix adhesion interactions is vital to
appropriate development and maintenance of all tissues,
including the epidermis (Barker and McGrath, 2001). Tumor
cells frequently show deregulated cadherin expression and
inappropriate switching among family members (Yilmaz and
Christofori, 2010). Immunohistochemical analyses of human
cutaneous SCC specimens have identified gain of N-cadherin
(Nguyen et al., 2011) and desmoglein 2 (Kurzen et al., 2003),
and loss of E-cadherin (Lyakhovitsky et al., 2004) and
glycosylphosphatidylinositol-anchored T-cadherin (T-cad)
(Takeuchi et al., 2002; Pfaff et al., 2010) as candidate
participants in the development of incipient invasive SCC.
Knowledge regarding molecular mechanisms whereby T-
cad participates in SCC progression is scant. Loss of T-cad
expression through allelic loss or aberrant gene methylation
in invasive cutaneous SCC was reported (Takeuchi et al.,
2002). Analysis of T-cad expression in relation to histological
classification of degree of differentiation revealed that T-cad
loss in cutaneous SCC was not ubiquitous but occurred
locally in association with histological features of a poten-
tially more malignant and invasive phenotype (Pfaff et al.,
2010). In vitro studies using HSC-1 or A431 SCC cell lines
collectively demonstrated that T-cad silencing increased
migratory, invasive, and proliferation potential, whereas the
converse was true for T-cad overexpression (Mukoyama
et al., 2005; Pfaff et al., 2010, 2011). However, in a murine
xenograft model, either gain or loss of T-cad in A431
increased tumor expansion in vivo (Pfaff et al., 2011). This
paradox was attributed to enhanced vascular endothelial
cell growth factor–mediated enhancement of angio/lymphan-
giogenesis for T-cad overexpression, and to enhanced
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EGF/extracellular signal–regulated kinase-mediated prolifera-
tion for T-cad silencing.
Potential linkage between EGF and T-cad warrants
attention. More than 90% of SCCs express elevated levels
of EGFR. EGFR has a crucial role in SCC proliferation,
invasion, and metastasis, and gathering evidence suggests
that EGFR-directed therapies may be useful adjuncts to
surgical treatment for SCC (Fung and Grandis, 2010).
Understanding mechanisms underlying enhanced EGFR
expression and/or activity is important for optimization of
EGFR-directed therapies. This study investigated whether and
how T-cad expression impacts invasive and motogenic
responses of A431 to EGF. We report that T-cad modulates
responsiveness of the EGFR pathway to EGF by influencing
membrane compartmentalization of the receptor. Silencing
or overexpression of T-cad, respectively, facilitates or impedes
ligand-dependent EGFR activation, with similar significance
for adhesion, motility, and invasion responses of SCC
to EGF.
RESULTS
Ectopic alterations of T-cad expression in A431 cells are not
accompanied by changes in markers of EMT but alter sensitivity
of cells to EGFR inhibitors
This study used SCC cell line A431 stably transduced with
respect to either T-cad overexpression (Tþ ; using pLVX-puro
vector carrying human T-cad complementary DNA) or T-cad
silencing (sT; using pLKO.1-puro vector carrying T-cad short
hairpin RNA), and stably transduced with empty pLVX-puro
vector (E) or pLKO.1-puro vector carrying random short hairpin
RNA (sT) as the respective controls (Pfaff et al., 2010).
Supplementary Figure S1 online shows levels of T-cad protein
and transcript expression in the transductants. We previously
reported that motile and invasive capacities of Tþ and sT were
decreased and increased, respectively (Pfaff et al., 2010), but
did not investigate mechanisms underlying these phenomena.
The occurrence of epithelial-to-mesenchymal transition
(EMT) is commonly associated with migration and invasion of
tumor cells (Yilmaz and Christofori, 2010). Immunofluores-
cence microscopy (Supplementary Figure S2 online), im-
munoblotting (Pfaff et al., 2010), and quantitative PCR
analysis (data not shown) revealed no influence of T-cad
expression on either levels or cellular distribution of E-
cadherin, P-cadherin, or vimentin. N-cadherin was not
detectable with any analytical method applied (data not
shown). As T-cad silencing in normal keratinocytes also
increases migratory-invasive capacities and fails to influence
epithelial and mesenchymal marker levels (Pfaff et al., 2010),
loss of T-cad in SCC likely affects migration and invasive
behavior by mechanisms different from those typically
associated with EMT (Yilmaz and Christofori, 2010).
As an alternative to EMT-based mechanisms, we considered
whether effects of T-cad on A431 motile-invasive behavior
involve EGFR pathway activity. A431 expresses high levels
of EGFR, which, although making cell proliferation less
dependent on exogenous EGF (Fan et al., 1994), enhances
EGF-induced motogenic responses (Malliri et al., 1998).
Assays of three-dimensional–spheroid invasion (Figure 1a)
and of transwell migration (Supplementary Figure S3 online)
confirmed (Pfaff et al., 2010) decreased and increased
invasiveness, respectively, for Tþ and sT, and further
demonstrated that invasion (Figure 1b) and transmigration
(Supplementary Figure S3 online) by Tþ was less sensitive
than sT to EGFR tyrosine kinase inhibitors gefitinib or lapatinib.
These data infer EGFR pathway inhibition in Tþ , and raise the
possibility that T-cad expression levels regulate EGFR-depen-
dent motile-invasive responses in A431.
T-cad expression levels modulate EGFR activity and
internalization
To determine whether T-cad expression might influence
EGFR activity, we examined indices of EGFR activation at the
level of EGFR itself, namely EGFR phosphorylation and
internalization (Schlessinger, 2000; Sorkin and Goh, 2009).
T-cad overexpression in the SCC cell line HSC-1 was
reported to result in constitutive reduction of total and
phosphorylated EGFR (p-EGFR) levels (Mukoyama et al.,
2007). We found that neither T-cad overexpression nor T-cad
silencing in A431 affected constitutive levels of total or
p-EGFR (Figure 1c). However, upon EGF stimulation sT
exhibited more prompt and amplified EGFR phosphorylation,
whereas this was blunted in Tþ (Figure 1c). EGF-induced
loss of total EGFR occurred faster in sT and was delayed in
Tþ (Figure 1c). We next applied an immunofluorescence-
based method (Francavilla et al., 2009) that allows monitor-
ing of receptor internalization. As expected, EGFR staining at
cell–cell contacts was prominent at baseline and weakened
upon EGF stimulation in association with increased intracel-
lular staining (Figure 2a, Supplementary Figure S4 online, no
acid wash). EGF-induced internalization occurred faster in sT
and was delayed in Tþ (Figure 2a, Supplementary Figure S4
online, with acid wash). Even at baseline, sT exhibited greater
intracellular staining than Tþ . To obtain biochemical
evidence for differences in plasma membrane-to-intracellular
translocation of EGFR, we performed immunoblotting using
lysates from cells collected without trypsinization (total
EGFR) or after trypsinization (internalized EGFR). Intracellular
EGFR levels under basal and EGF-stimulated conditions were
elevated in sT and lowered in Tþ (Figure 2b). Nuclear EGFR
and p-EGFR levels were examined by immunoblotting of
nuclear extracts. Purity of nuclear extracts was checked by
immunoblotting for nuclear marker lamin A/C (positive),
plasma membrane markers E-cadherin and ZO-1 (negative),
and cytoplasm markers glyceraldehyde-3-phosphate dehy-
drogenase and Grp78 (negative) (Supplementary Figure S5
online). At baseline, EGFR and p-EGFR levels were higher in
sT with a trend toward decrease in Tþ (Figure 2c). Upon EGF
stimulation, nuclear EGFR and p-EGFR levels increased in all
transductants, but the increase was augmented for sT and
blunted for Tþ (Figure 2c). Thus, T-cad silencing or T-cad
overexpression, respectively, facilitates or impedes EGFR
activation.
T-cad promotes retention of EGFR in lipid raft domains
Changes in EGFR membrane compartmentalization have a
major role in its activation: in the basal state EGFR partitions
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into lipid raft domains of the plasma membrane, and
sequestration of EGFR within the rafts exerts inhibitory effects
on EGFR signaling (Pike, 2005; Balbis and Posner, 2010). As
T-cad is also resident within lipid raft domains (Philippova
et al., 1998), we considered whether its expression level
might influence EGFR localization and/or retention. Confocal
microscopy images of empty vector and non-target short
hairpin RNA–transduced cells double-stained for EGFR/T-cad
depicted similar labeling patterns, with prominent co-staining
at cell–cell contacts (Figure 3a). Co-staining signal intensities
were enhanced in Tþ and negligible in sT (Figure 3a).
Isolation of membrane rafts using detergent and non-
detergent protocols (Figure 3b and c) revealed higher and
lesser co-fractionation of EGFR in T-cad- and caveolin-1-
enriched, clathrin-negative raft domains from Tþ and sT,
respectively. Reciprocal co-immunoprecipitation experi-
ments using a variety of detergent-based lysis buffer condi-
tions (Supplementary information online) failed to reveal
co-precipitation of EGFR with T-cad (Supplementary Figure
S6 online).
To ensure that our buffer conditions maintain protein–-
protein interactions that occur within lipid rafts, we probed
anti-EGFR immunoprecipitates for the presence of uPAR
(Supplementary Figure S6a online), a raft-associated protein
(Staubach and Hanisch, 2011) reported to complex with
EGFR (Liu et al., 2002; Mazzieri et al., 2006). We have
previously demonstrated association of T-cad with Grp78 and
integrin-linked kinase in endothelial cells (Joshi et al., 2007;
Philippova et al., 2008) but found no such associations in
A431 (data not shown), suggesting that T-cad may have
different membrane partners in different cell types. However,
we reconfirmed formation of T-cad–Grp78 and T-cad IL-8
complexes in endothelial cells (Supplementary Figure S7
online), thus validating our buffer conditions also in the case
of T-cad. Thus, EGFR and T-cad co-localize and T-cad
expression levels modulate retention of EGFR in raft domains,
but EGFR and T-cad appear not to be physically associated.
T-cad expression levels influence EGF-induced changes in cell
retraction and motility
Retractile and motile responses to EGF were examined using
time-lapse videomicroscopy and morphometric analysis. As
expected (Chinkers et al., 1981), EGF induces rapid cell
rounding and retraction from the substrate (Figure 4a). sT
exhibited more pronounced rounding/retraction, whereas the
response was reduced in Tþ (Figure 4a). Supplementary
videos S1 and S3 online illustrate distinct retraction
capacities of sT and Tþ . TRITC-phalloidin staining of cells
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Figure 1. T-cad expression levels in A431 alter sensitivity to EGFR inhibition and EGFR activity. (a, b) Matrigel-embedded spheroids were cultured for
3 days without (control) or with inclusion of lapatinib or gefitinib (1 mM in a, 0–1 mM in b). (a) Representative images of the spheroids are shown (bar, 200 mm
applicable to all images), **Po0.01. (b) **Po0.01 compares Tþ and sT for either gefitinib or lapatinib. (c) Cells were stimulated with EGF (10 ngml1) for the
indicated times. Whole-cell lysates were analyzed for p-EGFR and total EGFR by immunoblotting. GAPDH served as internal loading control. Alterations
in levels in E or Tþ and sC or sT are expressed relative to levels in E and sC controls, respectively. *P at least o0.01. E, empty vector cell; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase; p-EGFR, phosphorylated EGFR; sC, non-target short hairpin RNA cell; sT, T-cad-silenced cell; Tþ , T-cad-
overexpressing cell; T-cad, T-cadherin.
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cultured on gelatin-coated glass coverslips showed partial
reattachment to the substratum following prolonged
(24 hours) EGF stimulation. sT exhibited a retracted, poorly
spread morphology, and extensions were thread-like and
spiky, superficially resembling neurite-like protrusions,
whereas protrusions in Tþ were more broad and flattened
(Supplementary Figure S8 online).
To monitor the effects of T-cad on motility responses to
EGF, cells were seeded at lower density to minimize cell
clustering. EGF was added to the medium (Figure 4b) or
presented within a drop of polymerized fibrin (Figure 4c). In
both cases, movement speeds were increased and decreased
in sT and Tþ , respectively. With EGF added to the medium,
cell movement was associated with dynamic extension and
retraction of lamellipodia and filopodia, and, in accordance
with absence of a chemotactic gradient, the direction of
motility was random (Figure 4b). With fibrin-embedded EGF,
cells moved toward the source of EGF and with amoeboid
morphodynamics (Figure 4c).
T-cad expression levels influence basal and EGF-induced
changes in the activity of integrin b1 and Rho small GTPases
To investigate the molecular mechanisms underlying T-cad
effects on cell retraction and motility, we addressed activity
levels of integrin b1 and the Rho family of small GTPases,
which are crucial regulators of cell adhesion and migration
(Hood and Cheresh, 2002; Lozano et al., 2003). HUTS-4
antibodies, which specifically recognize the active confor-
mation of b1 integrins (Monaghan-Benson and McKeown-
Longo, 2006), were used to measure the levels of activated
integrin b1 on the cell surface. Under normal culture
conditions, sT contained higher levels of total integrin b1
and bound less HUTS-4 (Figure 5a). There were trends
toward reduced total integrin b1 and increased HUTS-4
binding in Tþ . Expression of data as an activity ratio (active
integrin b1/total integrin b1) revealed a significantly in-
creased integrin b1 activation in Tþ and confirmed the
decreased integrin b1 activation in sT. EGF-induced integrin
b1 activation was increased in Tþ but decreased in sT
(Figure 5b). EGF-induced activation of Rac1 and Cdc42 was
increased in Tþ but decreased in sT (Figure 6a and b).
Conversely, RhoA activation was decreased in Tþ and
increased in sT (Figure 6c). EGF-induced phosphorylation of a
20-kDa myosin light chain (MLC20) on threonine 20/serine
19, mediated by ROCK a downstream effector of Rho, was
higher in sT (Figure 6d). To confirm the involvement of RhoA
in T-cad-dependent effects on cell retraction, sT and Tþ
were co-transduced with adenovector expressing dominant-
negative mutant RhoA (Adv-N19RhoA). Videomicroscopy
(Supplementary videos S1, S2, S3 and S4 online) and analysis
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Figure 2. T-cad expression levels modulate EGFR internalization. (a) Alexa Fluor 488 IgG was used to visualize internalized EGFR (with acid wash) and
total EGFR (no acid wash) after live-cell incubation with anti-EGFR antibodies (bar, 20mm for all photomicrographs). (b) Immunoblotting for EGFR using
lysates from cells harvested without trypsinization (total EGFR) or after trypsinization (internalized EGFR). (c) Immunoblotting for EGFR in nuclear extracts.
EGFR and p-EGFR levels in Tþ and sT are expressed relative to those in their respective E and sC controls. *Po0.05, **Po0.01. E, empty vector cell;
GAPDH, glyceraldehyde-3-phosphate dehydrogenase; p-EGFR, phosphorylated EGFR; sC, non-target short hairpin RNA cell; sT, T-cad-silenced cell; Tþ ,
T-cad-overexpressing cell; T-cad, T-cadherin.
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of surface area coverage (Figure 6e) showed that N19RhoA
reduced the enhanced retraction of sT.
DISCUSSION
This study has identified T-cad as a negative auxiliary
regulator of EGFR pathway activation in SCC, with con-
sequences for functional responses of SCC to EGF. First,
spheroid invasion assay revealed that sTs were highly
sensitive to inhibition by EGFR inhibitors lapatinib and
gefitinib, indicating the contribution of EGFR pathway
activity to their increased invasive potential. Second, greater
responsiveness to EGF in sT was evident for many signaling
and functional events of the EGFR activation cascade (e.g.,
EGFR phosphorylation, internalization, nuclear translocation,
cell retraction/de-adhesion). The converse state of attenuated
responsiveness to EGF was true for Tþ . These data might be
interpreted to suggest that when T-cad is present in the cell
membrane it acts as a ‘‘brake’’ on EGFR signaling, whereas
loss of T-cad facilitates EGFR responsiveness and pathway
activation.
We explored mechanisms underlying T-cad-dependent
regulation of EGFR activity. Confocal microscopy revealed
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co-localization between T-cad and EGFR. However, based
on our failed attempts to co-precipitate T-cad and EGFR from
the plasma membrane, direct interaction between the two
proteins would seem unlikely. Another possibility is that
T-cad influences membrane distribution of EGFR. Several
studies (reviewed in Pike, 2005; Balbis and Posner, 2010)
have demonstrated that EGFR activity depends on its
localization within lipid rafts, which are specialized domains
of the plasma membrane that are enriched in sphingolipids
and sterols and act as assembly platforms for receptors and
their partner signaling molecules. Raft disruption resulted in
loss of IgCAM-mediated EGFR activation in the olfactory
system (Gibson et al., 2009), suggesting that intactness of
lipid raft platforms is prerequisite for EGFR function. On
the other hand, evidence also supports the fact that lipid
rafts negatively regulate EGFR activity by inhibiting lateral
movement of EGFR and decreasing probability of EGFR
dimerization. EGFR was inactivated when trapped in raft
compartments (Mineo et al., 1999), whereas binding of
cognate ligands to EGFR caused its release out of lipid rafts,
dimerization, and stimulation of tyrosine kinase activity
(Lambert et al., 2006). Raft destruction caused EGF-depen-
dent hyperactivation of Erk1/2 (Furuchi and Anderson, 1998).
It also induced spontaneous activation of EGFR even in the
absence of ligand by causing its release into small confined
domains of the plasma membrane where the receptors
dimerize and autophosphorylate their cytoplasmic domains
owing to their high density and/or separation from inhibitory
molecules that associate with the receptors in rafts (Pike and
Casey, 2002; Ringerike et al., 2002; Lambert et al., 2006).
Our analysis of EGFR levels in lipid raft domains provides
evidence that T-cad upregulation in A431 leads to retention
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of EGFR in lipid rafts, whereas T-cad silencing releases EGFR
from this compartment. This, taken together with the
differential EGF responsiveness of Tþ (decreased) and sT
(increased) would be concordant with the view that lipid raft
localization negatively regulates EGFR activity.
As it is T-cad downregulation/loss that occurs in vivo in
invasive SCC tumor specimens (Takeuchi et al., 2002; Pfaff
et al., 2010), a central issue of the study concerns
consequences of T-cad loss on EGF-dependent modulation
of signaling systems controlling SCC migration and invasion.
We found that sT exhibited increased total levels of integrin
b1, whereas their integrin b1 activation status (active/total
integrin b1 ratio) was decreased. The latter is consistent with
increased EGFR activity in sT, which may promote integrin
b1 internalization (Mukoyama et al., 2007) and therefore
inactivation. Many studies demonstrate associations between
regulation of integrin expression and cancer. Changes in
integrin patterns allow recognition of variable matrices by
cancer cells and modulate signaling and gene expression
(Hood and Cheresh, 2002). It is widely held that integrin b1
is required for cancer cell motility and invasion. Therefore,
the finding that sT (which are characterized by enhanced
invasive potential) display decreased integrin b1 activity
was somewhat unexpected. However, SCC cancers are
heterogeneous and may exhibit variable alterations in
integrin expression and function (Janes and Watt, 2006).
Integrin b1 is overexpressed in cervical SCC (Hughes et al.,
1994) and vulvar SCC particularly at the invading tumor
borders (Brockbank et al., 2005). In contrast, reduced
expression of integrin b1 was reported in oral SCC (Jones
et al., 1993; Bagutti et al., 1998). Lower expression of integrin
b1 at the invasive front of oral SCC correlated with poor
prognosis (Ohara et al., 2009). There are also some
ambiguities with respect to participation of integrin b1 in
EGFR-modulated SCC growth and differentiation. Forced
expression of integrin b1 in the suprabasal layer of the
epidermis suppresses cell differentiation and cell cycle exit
(Carroll et al., 1995), possibly by promoting Erk1/2
activity (Zhu et al., 1999). In contrast, in oral SCC cell line
SCC4, which expresses an inactive mutant integrin b1 and is
poorly differentiated, the introduction of wild-type integrin
b1 stimulates differentiation (Evans et al., 2003), whereas
integrin b1 knockdown in A431 fails to affect either
proliferation or Erk1/2 activity in vitro or in vivo (Brockbank
et al., 2005).
Decreased basal activity and EGF-dependent inactivation
of integrin b1 in sT might be related to two phenomena. First,
initiation of SCC motility by EGF involves cell morphology
changes including cytoskeleton rearrangement, remodeling
of cell–matrix contacts, loss of stress fibers, induction of
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Figure 5. T-cad expression affects constitutive integrin b1 activity and EGF-induced integrin b1 activation. Integrin activation under normal culture conditions
(a) or following EGF stimulation (10 ngml1, 15minutes; b) was measured using the HUTS-4 antibody specific for activated integrin b1. Cells were exposed
to MnCl2 (5mM) as positive control. Typical blots are shown. The higher mass of active integrin b1 (218 kDa) derives from the complex of integrin b1
(130 kDa) and HUTS-4 antibody (88 kDa). Total and active integrin b1 levels are presented individually or as a ratio (active b1/total b1), and changes in
Tþ or sT are expressed relative to values in their respective E and sC controls; *Po0.05, **Po0.01, ***Po0.001. E, empty vector cell; GAPDH,
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cortical actin polymerization, and cell rounding. Although
integrins may be needed for later cell motility, the initial
response to EGF is associated with loss of cell–matrix
attachments (Hauck et al., 2001). The fact that sT exhibit
pronounced EGF-induced integrin b1 inactivation together
with rapid disassembly of cell–matrix contacts, cell retraction,
and rounding may reflect a generally enhanced EGFR
activation status. Decreased basal integrin b1 activity in sT
might be explained by residual EGFR activity even in the
absence of high concentrations of exogenous EGF, invoking a
possibility that in vivo T-cad loss may contribute to both
ligand-dependent and -independent EGFR activation. Sec-
ond, decreased integrin b1 activity may be associated with a
specific type of cell motility. Single cancer cells may move
using at least two distinct migration modes, namely
mesenchymal or amoeboid migration (Lammermann and
Sixt, 2009; Yamazaki et al., 2009; Parri and Chiarugi, 2010;
Yilmaz and Christofori, 2010). Mesenchymal migration is
characterized by elongated morphology, clear front-to-rear
end polarization, well-formed lamellipodia, dependence on
integrins and matrix metalloproteinases, and increased Rac1
signaling. Cells moving in an amoeboid manner exhibit
rounded morphology with bleb-like protrusions, decreased
adhesion to the surface, integrin inactivation, and concomi-
tant changes in small GTPases activity, namely, Rac1
inhibition and RhoA/ROCK activation. In accordance with
literature (Malliri et al., 1998; Sahai, 2007), our videomicro-
scopy experiments demonstrate that A431 may migrate in an
amoeboid manner. Furthermore, the nature of changes in
activities of integrin b1 (decreased) and small GTPases (Rac1
decreased, RhoA increased) in sT is precisely that expected
for enhanced amoeboid motility (Lammermann and Sixt,
2009; Yamazaki et al., 2009; Parri and Chiarugi, 2010).
In vivo, such alterations in cell phenotype and integrin-
dependent adhesion may contribute to more active migration
and chemotaxis, leading to increased tumor cell dissemina-
tion (Kren et al., 2007).
Literature evidence supports the existence of a broad
spectrum of membrane molecules acting as auxiliary regula-
tors (‘‘co-receptors’’) of growth factor receptor activity
(Kirkbride et al., 2005). Fine-tuning of receptor activation is
often achieved by their rapid redistribution into various
plasma membrane domains or internalization, allowing fast
association of the receptor with various scaffolds and adaptors
or signal attenuation. This enables prompt cell reactions to the
changing environment, which is particularly important, for
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example, for directed migration during angiogenesis, neurite
outgrowth, or tumor front invasion. Examples of such paired
regulation are interplay between neural cell adhesion
molecule NCAM and fibroblast growth factor receptor
FGFR-1 in tumor dissemination (Francavilla et al., 2009;
Zecchini et al., 2011), IgCAM-mediated EGFR activation in
the developing olfactory pathway (Gibson et al., 2009), and
others (Kirkbride et al., 2005). Many of these ‘‘co-receptors’’,
such as T-cad, are surface adhesion molecules localizing in
lipid rafts that link signaling components together and
define the mechanism of receptor complex activation,
stabilization, or internalization. We invoke T-cad as a
further example of a ‘‘co-receptor’’ involved in spatial and
temporal adjustment of cell sensitivity to growth and
chemotactic signals. Specific molecular mechanisms of
T-cad-dependent regulation of EGFR compartmentalization
and its consequences (e.g., ligand binding, receptor
dimerization, interaction with adaptor proteins) are yet to
be elucidated.
In conclusion, loss of T-cad in SCC may lead to ligand-
dependent EGFR hyperactivation with resultant exaggeration
of invasive and aggressive tumor behavior. Epigenetic studies
(reviewed in Lochter et al., 1997) have reported silencing of
T-cad gene CDH13 also in melanomas and other malig-
nancies (e.g., breast, pancreatic, lung, ovarian, inter alia) in
which enhanced EGFR activity frequently occurs. Therefore,
it is pertinent to consider whether suppression of EGFR
pathway activation might be a common tumor suppressor
mechanism of T-cad.
MATERIALS AND METHODS
Cell culture
Lentivector-mediated generation of A431 (epidermoid carcinoma of
skin; ATTC (Manassas, VA), CRL-1555) stably transduced with
respect to T-cad overexpression (Tþ ) or T-cad deficiency (sT), and
with empty vector (E) or non-target short hairpin RNA (sC) cells as
respective controls, has been described (Pfaff et al., 2010). Cells
were normally cultured in DMEM containing 10% fetal calf serum
(DMEM/fetal calf serum) and were serum deprived culture for
40 hours in DMEM containing 0.1% BSA (DMEM/BSA) before EGF
stimulation (10 ngml1).
Invasion and transmigration assays
Spheroid invasion and transwell migration assays were performed as
described (Pfaff et al., 2010), with minor modifications (Supplemen-
tary information online).
Fluorescence microscopy
Fluorescence microscopy techniques have been described (Philippova
et al., 2003, 2005; Pfaff et al., 2010). Staining protocols, antibody
sources, and information on microscopes, cameras, and acquisition
software are detailed in Supplementary information online.
Time-lapse videomicroscopy analysis of cell surface area and
cell motility
Time-lapse videomicroscopy techniques have been detailed (Kyr-
iakakis et al., 2010). Seeding densities, acquisition, and morpho-
metric analytical methods are detailed within Supplementary
information online. Images were acquired at a rate of 1 frame per
5minutes for 15minutes to record early retraction/spreading or 1
frame per 5 or 10minutes for 18–24 hours to record motility.
Assays for EGFR internalization and translocation
EGFR internalization was monitored using a previously described
live-staining immunofluorescence-based method (Francavilla et al.,
2009) with minor modifications (Supplementary information online).
Mouse anti-EGFR IgG (Ab-5, clone H11) and anti-mouse Alexa Fluor
488 IgG were used for EGFR detection. Plasma membrane–
to-intracellular translocation of EGFR was determined using
conventional nuclear fractionation and monolayer trypsinization
approaches (Supplementary information online).
Lipid rafts isolation
Lipid rafts were isolated following exact protocols described for
detergent (Triton X-100)-based isolation/fractionation through a
5–30% sucrose gradient (Philippova et al., 1998) and non-detergent-
based isolation/fractionation through a gradient of 0–20%-Optiprep
(Nycomed Pharma AS, Oslo, Norway; Macdonald and Pike, 2005).
Assays for activity of Rho small GTPases
Pull-down assay for quantification of active guanosine triphosphate-
bound Rac1 and Cdc42 was performed as described (Ren and
Schwartz, 2000), with minor modifications (Supplementary informa-
tion online). RhoA GTPase activity was determined using the G-LISA
RhoA Activation Assay Kit (Cytoskeleton, Denver, CO).
Measurement of the occupied, active conformation of
integrin b1
Activated integrin b1 was detected using HUTS-4 mAbs as described
(Monaghan-Benson and McKeown-Longo, 2006), with minor
modifications (Supplementary information online).
Immunoblotting
SDS-PAGE and immunoblotting protocols have been detailed
(Kuzmenko et al., 1998). Primary antibodies against the following
proteins were used: T-cad, caveolin 1, clathrin heavy chain, RhoA,
Rac1, Cdc42, EGFR, p-EGFR(Tyr1068), p-MLC20
(Thr18/Ser19), human
integrin b1, glutathione S-transferase, ZO-1, lamin A/C, and
glyceraldehyde-3-phosphate dehydrogenase. Sources of primary
and secondary antibodies are given in Supplementary information
online. Representative blots are shown.
Statistical analysis
All experiments were conducted on at least three separate occasions,
and unless otherwise stated all results are given as mean±SD.
Differences were determined using one-way repeated measures
analysis of variance with Tukey’s multiple comparison using the
GraphPad Prism 5.0 software (GraphPad Software, San Diego, CA).
Po0.05 was considered significant.
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